IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

(2015) Yuchen Jiao et al.   Oncotarget

Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide

(2013) Nicole A. Shonka et al.   JOURNAL OF NEURO-ONCOLOGY

Interlaboratory comparison of IDH mutation detection

(2013) Martin J. van den Bent et al.   JOURNAL OF NEURO-ONCOLOGY

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas

(2012) Felix Sahm et al.   ACTA NEUROPATHOLOGICA

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial

(2012) Monika E. Hegi et al.   ACTA NEUROPATHOLOGICA

The Definition of Primary and Secondary Glioblastoma

(2012) H. Ohgaki et al.   CLINICAL CANCER RESEARCH

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas

(2011) Michael Weller et al.   GLIA

Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin

(2011) Albert Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

(2011) Stephen Yip et al.   JOURNAL OF PATHOLOGY

Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma

(2011) C. Bettegowda et al.   SCIENCE

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults

(2010) Kaisorn L. Chaichana et al.   JOURNAL OF NEUROSURGERY

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

(2010) C. Houillier et al.   NEUROLOGY

Monoclonal antibody specific for IDH1 R132H mutation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas

(2009) Takuya Watanabe et al.   AMERICAN JOURNAL OF PATHOLOGY

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

(2009) Koichi Ichimura et al.   NEURO-ONCOLOGY

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

(2009) H. J. Dubbink et al.   NEUROLOGY

EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME

(2009) et al.   NEUROSURGERY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations

(2009) Cameron Brennan et al.   PLoS One

Analysis of the IDH1 codon 132 mutation in brain tumors

(2008) Jörg Balss et al.   ACTA NEUROPATHOLOGICA

Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas

(2008) Justin S. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE